IQVIA (NYSE:IQV) Issues Quarterly Earnings Results

IQVIA (NYSE:IQV) posted its quarterly earnings data on Thursday. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21), Zacks reports. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. IQVIA updated its FY 2025 guidance to 11.700-12.100 EPS.

IQVIA Price Performance

Shares of NYSE:IQV opened at $208.13 on Friday. IQVIA has a one year low of $187.62 and a one year high of $261.73. The stock has a market cap of $37.78 billion, a PE ratio of 27.75, a price-to-earnings-growth ratio of 2.25 and a beta of 1.48. The business’s fifty day moving average price is $200.67 and its two-hundred day moving average price is $219.54. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.81 and a current ratio of 0.84.

Insider Activity

In other news, Director John G. Danhakl bought 1,275 shares of the business’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was purchased at an average price of $200.58 per share, with a total value of $255,739.50. Following the purchase, the director now owns 1,275 shares of the company’s stock, valued at $255,739.50. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 1.60% of the company’s stock.

Analyst Ratings Changes

IQV has been the subject of several recent research reports. Deutsche Bank Aktiengesellschaft decreased their price target on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a report on Friday, November 1st. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a report on Thursday, November 28th. Truist Financial reduced their price target on IQVIA from $265.00 to $261.00 and set a “buy” rating for the company in a report on Thursday, December 12th. Robert W. Baird dropped their price objective on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, January 21st. Finally, JPMorgan Chase & Co. decreased their target price on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 5th. Five investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $252.39.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.